ORPHAN TECHNOLOGIES
Orphan Technologies is committed to reduce the burden of patients suffering from homocystinuria. OT-58, their lead drug development candidate, has been optimized as an enzyme replacement therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.
ORPHAN TECHNOLOGIES
Industry:
Therapeutics
Address:
Rapperswil, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.orphantechnologies.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving Amazon Google Apps For Business ReCAPTCHA GoDaddy DNS ReCAPTCHA V2 Amazon Frankfurt Region Media Temple
Similar Organizations
Affini-T Therapeutics
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Chaperone Therapeutics
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Lannett Company
Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.
Official Site Inspections
http://www.orphantechnologies.com
- Host name: acsmekekqc.gs10.mtsvc.net
- IP address: 64.207.139.130
- Location: Culver City United States
- Latitude: 34.0141
- Longitude: -118.3983
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90232
More informations about "Orphan Technologies"
Orphan Technologies - Crunchbase Company Profile
Orphan Technologies is committed to reduce the burden of patients suffering from homocystinuria. OT-58, their lead drug development candidate, has been …See details»
Orphan Technologies 2025 Company Profile: Valuation, …
Orphan Technologies is headquartered in London, United Kingdom. What is the size of Orphan Technologies? Orphan Technologies has 10 total employees. …See details»
Orphan Technologies Company Profile | Management and
Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare disorder, classical homocystinuria, and related diseases. OT …See details»
Orphanet: ORPHAN TECHNOLOGIES LTD.
ORPHAN TECHNOLOGIES LTD. institutions.detail.person.activities. Private for profit funding body Sponsor of orphan designation Orphan Technologies Ltd. Orphan Technologies Ltd. …See details»
Orphan Technologies Overview | SignalHire Company Profile
Orphan Technologies is a private company that has been in the industry for 11 years. The company currently specializes in the Biotechnology, Biotechnology, Pharmaceuticals areas. …See details»
Orphan Technologies - Craft
Orphan Technologies Summary. Company Summary. Overview. Orphan Technologies is a biotech company developing a drug for homocystinuria. It offers OT-58, an enzyme …See details»
Orphan Technologies Headquarters and Office Locations - Craft
Orphan Technologies Headquarters and Office Locations. Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit. Button CTA. Orphan Technologies is headquartered in …See details»
Orphan Technologies - VentureRadar
Orphan Technologies VentureRadar profile. Find out more about Orphan Technologies, Biologics and Stem Cells and Cellular Therapy.See details»
Orphan Technologies Ltd.:Company Profile & Technical Research ...
Orphan Technologies Ltd. is a company that provides Homocystinuria, Medicine, Pharmacy and Therapeutics and more. Orphan Technologies Ltd. is headquartered in Switzerland ZURICH. …See details»
Retrophin Completes Acquisition of Orphan Technologies
About Orphan Technologies. Orphan Technologies is a clinical-stage biopharmaceutical company focused on the development of OT-58. OT-58 is an investigational human enzyme …See details»
Orphan Technologies | LinkedIn
Orphan Technologies | 77 followers on LinkedIn. Orphan Technologies is committed to reduce the burden of patients suffering from homocystinuria. | Orphan Technologies is committed to …See details»
Orphanet: Orphan Technologies Ltd.
Orphan Technologies Ltd. Zuercherstrasse 19. CH-8640 RAPPERSWIL . SWITZERLAND. Contact email: [email protected]. Institution's website Contacts. Professionals: …See details»
Orphan Technologies acquired by Travere Therapeutics
Oct 22, 2020 Orphan Technologies Orphan Technologies is committed to reduce the burden of patients suffering from homocystinuria. Acquiring Organization: Travere Therapeutics Travere …See details»
Orphan Technologies Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Orphan Technologies Ltd. with its drug pipeline, therapeutic area, technology platform, 4 news, and 5 literature, Disease Domain:Endocrinology and Metabolic ...See details»
Orphan Technologies - Golden
Orphan Technologies is a biotechnology company developing enzyme therapies for treating homocystinuria. Overview Structured Data Issues Contributors Activity. Contents. …See details»
Retrophin Announces Agreement to Acquire Orphan
Oct 22, 2020 Orphan Technologies is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare …See details»
Retrophin Acquires Orphan Technologies to Develop Potential, …
Oct 25, 2020 By Judy Ya-Hsuan Lin. O n October 22nd, San Diego-based Retrophin announced they would acquire Lexington, MA-based Orphan Technologies with an upfront payment of …See details»
Retrophin Announces Agreement to Acquire Orphan Technologies
Oct 20, 2016 SAN DIEGO -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, …See details»
Orphanet: Orphan Technologies Ltd.
Orphan Technologies Ltd. Orphan Technologies Ltd. Zuercherstrasse 19. CH-8640 RAPPERSWIL . SCHWEIZ. E-Mail: [email protected]. Webseite der Einrichtung …See details»
Retrophin buys up Orphan Technologies, spending $90M on rare …
Oct 23, 2020 Retrophin has snapped up Orphan Technologies for a $90 million upfront payment, gaining access to the biotech's rare metabolic disorder drug OT-58. The enzyme replacement …See details»